Share Prices & Company Research

Market News

18 Jan 2021 | 10:23

SourceBio sees 'considerable growth' in FY revenues, EBITDA

(Sharecast News) - Laboratory services and products provider SourceBio said on Monday that full-year results would be in line with market expectations after it recorded "considerable growth" in both revenues and underlying earnings year-on-year. SourceBio expects to report revenues of approximately £50.7m for 2020, more than double the £21.2m recorded in 2019, while adjusted underlying earnings for the year ended 31 December was approximately £14.0m, an almost fivefold increase on 2019.

The AIM-listed group added that following careful working capital management, its cash position was also "well ahead of market expectations" with cash at 31 December 2020 of £8.4m and also noted that it had eliminated all outstanding bank and shareholder borrowings.

SourceBio also stated trading had started strongly in 2021 but said it was anticipating reduced demand for its Cellular Pathology testing services into the new year as a result of the UK's third national lockdown.

Chairman Jay LeCoque said: "I am pleased to report to shareholders significant revenue growth with dramatically increased profitability in an extremely busy year for SourceBio, that included a successful AIM listing in October.

"The results have been dominated by robust Covid-19 testing services and, given the impact of the Covid-19 pandemic, the board remains pleased with performance across all areas of the business. The company remains strongly capitalised with a loan-free balance sheet which positions us well to deliver further aggressive growth in 2021."

As of 1020 GMT, SourceBio shares were up 1.37% at 222.0p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.